Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$97.88
+1.2%
$108.79
$81.20
$131.49
$23.53B1.39964,014 shs1.41 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$49.44
-3.3%
$39.45
$29.31
$59.39
$5.92B0.621.86 million shs1.74 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$27.99
+0.6%
$23.55
$17.24
$28.75
$17.96B0.931.45 million shs1.54 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$18.90
-5.2%
$17.31
$12.47
$22.80
$21.68B0.7211.98 million shs12.25 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%-13.98%-14.78%-9.02%-21.60%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
0.00%-3.55%+32.22%+51.36%-8.50%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+1.02%+19.35%+21.70%+3.42%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.00%+5.41%+11.76%+14.09%+8.42%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$97.88
+1.2%
$108.79
$81.20
$131.49
$23.53B1.39964,014 shs1.41 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$49.44
-3.3%
$39.45
$29.31
$59.39
$5.92B0.621.86 million shs1.74 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$27.99
+0.6%
$23.55
$17.24
$28.75
$17.96B0.931.45 million shs1.54 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$18.90
-5.2%
$17.31
$12.47
$22.80
$21.68B0.7211.98 million shs12.25 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%-13.98%-14.78%-9.02%-21.60%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
0.00%-3.55%+32.22%+51.36%-8.50%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+1.02%+19.35%+21.70%+3.42%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.00%+5.41%+11.76%+14.09%+8.42%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.76
Moderate Buy$135.8038.74% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.87
Moderate Buy$75.3852.48% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.70
Moderate Buy$39.2540.23% Upside
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
3.25
Buy$24.7130.76% Upside

Current Analyst Ratings Breakdown

Latest CYTK, BNTX, TEVA, and GMAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$136.00
9/3/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$53.00 ➝ $71.00
9/3/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$60.00 ➝ $80.00
9/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$77.00 ➝ $84.00
9/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$87.00 ➝ $96.00
9/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$78.00
9/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$72.00
8/19/2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/15/2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$35.00 ➝ $36.00
8/14/2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$138.00 ➝ $136.00
(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$2.98B7.90N/AN/A$87.61 per share1.12
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$18.47M320.30N/AN/A($1.15) per share-42.99
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.12B5.75$1.53 per share18.35$8.04 per share3.48
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$16.63B1.30$3.19 per share5.92$4.74 per share3.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$719.92M-$1.60N/AN/AN/A-12.20%-1.84%-1.59%11/3/2025 (Estimated)
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$589.53M-$5.10N/AN/AN/A-707.17%N/A-45.52%11/5/2025 (Estimated)
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$1.14B$1.9914.0715.721.6237.53%21.03%16.98%11/6/2025 (Estimated)
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$0.16N/A7.191.16-0.95%46.10%7.18%11/5/2025 (Estimated)

Latest CYTK, BNTX, TEVA, and GMAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.34-$1.12+$0.22-$1.12$1.95 million$66.77 million
8/7/2025Q2 2025
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.39$0.54+$0.15$0.54$5.77 billion$925.00 million
8/4/2025Q2 2025
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.41-$1.60-$0.19-$1.82$161.26 million$306.46 million
7/30/2025Q2 2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.64$0.66+$0.02$0.24$4.34 billion$4.18 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$1.015.35%N/AN/A N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.61
8.48
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
6.76
6.76
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/A
6.22
6.20
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.45
1.06
0.77

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
54.05%

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
3.40%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
0.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
6,772240.40 million194.24 millionOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.66 million115.59 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2,682641.59 million631.71 millionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
36,8301.15 billion1.14 billionOptionable

Recent News About These Companies

Zacks Research Has Pessimistic Outlook of TEVA Q3 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioNTech stock logo

BioNTech NASDAQ:BNTX

$97.88 +1.14 (+1.18%)
Closing price 04:00 PM Eastern
Extended Trading
$97.55 -0.33 (-0.34%)
As of 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$49.44 -1.69 (-3.31%)
Closing price 04:00 PM Eastern
Extended Trading
$49.48 +0.04 (+0.07%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$27.99 +0.17 (+0.61%)
Closing price 04:00 PM Eastern
Extended Trading
$27.99 0.00 (0.00%)
As of 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$18.90 -1.03 (-5.17%)
Closing price 03:59 PM Eastern
Extended Trading
$18.92 +0.02 (+0.11%)
As of 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.